Mebufotenin

5-MeO-DMT

Open Mebufotenin in the interactive console ↗

Mebufotenin ballicule: receptor binding, kinetics and half-life diagram — Mechanism of action: Mebufotenin ballicule

What it isUltra-short-acting tryptamine psychedelic, the compound in Sonoran Desert toad venom; investigational as a single inhaled or nasal dose for treatment-resistant depression.

Why this oneEffects last under an hour, against about 12 hours for lysergide, so a session fits a clinic visit. Unlike the other classic psychedelics, its 5-HT1A affinity exceeds its 5-HT2A affinity.

What limits itMAO-A clears it: with an MAOI, including the harmala alkaloids of ayahuasca, levels rise sharply and serotonin toxicity deaths are reported. Schedule I; not approved.

Mebufotenin molecular structure (skeletal formula) — Molecular structure: Mebufotenin

Used for

treatment-resistant depression (phase 2b; FDA breakthrough designation)

NO BOXED WARNINGS

Principal riskSerotonin toxicity, including deaths, when combined with MAOIs

Classes and tags

Serotonin and MAOI

Provisional washout figures

SRI significance0 / 4

MAO-A inhibition0 / 4

Serotonin release0 / 4

Elevating mechanism5-HT1A/5-HT2A agonist (MAO-A substrate)

Evidence confidenceModerate

InterpretationMAOIs (including harmala alkaloids) markedly raise and prolong exposure; serotonin syndrome and deaths are reported. Never combine.

Open Mebufotenin in the interactive console ↗